Haishi, the headquarters of Xinmei Pharmaceutical Group.
As one of the top ten pharmaceutical groups in China, Xinmei owns a number of pharmaceutical patents and a variety of best-selling drugs. Recently, it caused a sensation on the Internet due to its millions-high price of anti-cancer injections.
They will also cooperate with top foreign pharmaceutical companies, such as exchanging patent technology licenses, or acting as agents to sell each other's drugs.
Today, Chairman Wu Shiji sat in the spacious and bright river view conference room and signed a patent licensing agreement for cardiovascular drugs with Pfizer.
Cardiovascular drugs are Pfizer's flagship products. After this iterative new drug was launched in Eagle Country last year, it has shown remarkable efficacy and has been greatly sought after by the market.
When Xinmei introduces this drug, it also wants to reach a series of cooperation with Pfizer in the field of anti-tumor drugs.
After all, Pfizer has a brilliant record in anti-cancer targeted drugs. It has targeted drugs and immune drugs for many cancers such as lung cancer and blood cancer.
Xinmei has recently developed a new drug for lymphoma and is actively deploying overseas markets. In-depth cooperation with Pfizer, the world's number one pharmaceutical company, is naturally inevitable.
Mr. Wu signed a contract with Dr. Andre, President of Pfizer Asia Pacific, and had an in-depth exchange of views on anti-cancer drug cooperation. Both parties were very satisfied.
Mr. Wu decided to express his host's enthusiasm: "Dr. Andre, we won't go home until we get drunk tonight."
Andre is a tall, blond, blue-eyed typical Westerner with a warm smile on his face.
He held Mr. Wu's hand and said in fluent Chinese: "Thank you very much Mr. Wu for your hospitality. I look forward to our future cooperation."
"However," he then shook his head, with a very regretful expression on his face: "I will go to nearby Kunming City tomorrow to attend a press conference of a local pharmaceutical company, and I will rush there tonight."
When Mr. Wu heard the name Kunshi, his face froze, and he forced a smile and asked, "Is it a pharmaceutical company called Sanqing?"
Andre nodded and smiled: "Yes, that pharmaceutical company announced that it has developed a broad-spectrum anti-cancer drug. It is said to be effective in three days. It is very miraculous and has very low side effects. It is said that they will announce the clinical results at the press conference tomorrow. I want to take a look at the test data.”
Mr. Wu was shocked. This anti-cancer drug from Sanqing Pharmaceutical actually alarmed Pfizer's Asia Pacific president?
Does Pfizer have any thoughts on this anti-cancer drug?
He looked at his assistant calmly: "Is Sanqing Pharmaceutical's press conference tomorrow?"
The assistant respectfully replied: "Yes, it will be tomorrow morning. They even sent an invitation specially before."
Mr. Wu nodded to Andre and said, "Well, Dr. Andre, I happen to be going to attend too, so why don't we go together."
Andre also said very happily: "That's great. We can continue to talk about cooperation on the way."
He suddenly smiled meaningfully: "We may meet many old friends at the venue tomorrow morning."
Mr. Wu was shocked. Are there other pharmaceutical giants interested in Sanqing's anti-cancer drugs?
Suddenly, an idea flashed through his mind. Andre came all the way from the imperial capital this time, and the time was so close to the press conference. Could it be that the main goal was Sanqing, not the cooperation agreement with Mr. Wu?
Thinking of this, the joy of signing the agreement suddenly disappeared completely, and Mr. Wu felt bad all over.
So he inquired about the other party's purpose of attending the press conference.
It's a pity that Andre remained tight-lipped and didn't talk about Sanqing Pharmaceutical. He only chatted with Mr. Wu about some interesting things about domestic life.
Mr. Wu returned without success and had no choice but to give up.
At nine o'clock the next morning, Mr. Wu and Andre arrived at the headquarters of Sanqing Pharmaceutical early.
As soon as I arrived at the gate, I saw that the parking lot was full of cars, and there was a long queue behind me. The roadside near the gate was full of cars.
The two got off the car with their assistant and checked in at the door. As soon as they arrived at the entrance of the administration building, they saw Sun Chengren walking over with a cheerful look on his face.
"Mr. Wu, Dr. Andre, thank you both very much for coming. Please come in."
Mr. Wu and Lao Sun have been acquaintances for many years, and they are also enemies. Seeing him at this time, he suddenly remembered the overwhelming criticism of Xin Mei on the Internet, and a resentment emerged in his heart, so he said in a sinister way: "Lao Wei has given birth to a good son. I have to come and take a good look, haha."
Lao Sun smiled slightly and pretended not to hear.
Andre was very enthusiastic towards everyone and took the initiative to greet Lao Sun for a while before walking into the hall with Mr. Wu.
Mr. Wu looked around the hall. It was very grandly decorated, with banners, flowers, etc. There were many chairs, and many people were already sitting on them.
At the end of the hall is a high platform with many cameras in front and a group of media reporters gathered under the stage.
Mr. Wu narrowed his eyes, looking for acquaintances and colleagues.
Andre, who was next to him, suddenly walked to the right, waving as he walked: "Dr. Schmitz, I didn't expect you to be here too. It's been a long time since I last saw you."
The right side was full of people, including many foreigners with tall noses and deep eyes. A middle-aged man with thick beard and hair stood up from the crowd, walked quickly towards Andre, and the two embraced warmly.
Andre was very happy to introduce Mr. Wu.
"Dear Wu, this is the global president of oncology at Merck. He was an old colleague of mine. I never expected that he would also be here."
This was a bearded foreigner with thick glasses and a scholarly air. He smiled and stretched out his hand and said: "Hello, Mr. Wu, our company has a global pharmaceutical center in nearby Hangzhou. I came here recently on a business trip and happened to hear something. A miraculous broad-spectrum anti-cancer drug was released, so I came to take a look.”
Mr. Wu chatted with him for a moment, and suddenly something happened in his mind. He remembered that Keytruda, the world's first broad-spectrum anti-cancer drug, is Merck's flagship product. Last year, sales reached tens of billions of dollars. In the first half of the year, it had been approved by the Food and Drug Administration. It is fully launched in the domestic market and is selling hotly.
He seemed to understand the purpose of these global pharmaceutical giants coming to take a look.
The anti-cancer drug market is indeed an extremely rich and sweet big cake. Every pharmaceutical giant is staring at it like a hungry wolf, greedily occupying every piece of territory, unwilling to retreat even a little bit, not to mention the huge domestic market. market is available for development.
Generally speaking, there are many types of cancer, and most treatment drugs are targeted drugs and immune drugs, which can only treat a specific cancer.
At present, targeted drugs can only cover a small number of cancers, and other cancers can only be treated with broad-spectrum anti-cancer drugs.
There are only three broad-spectrum anti-cancer drugs in the world, namely Merck's Keytruda, Roche's entrectinib, and larotrectinib.
Keytruda is Merck's blockbuster anti-cancer drug, which has shown gratifying effects on many types of cancer. It became famous for curing Carter, the former President of the Eagle Nation, who was in his 90s.
Keytruda has entered the domestic market, and the remaining two drugs are currently only sold abroad due to their high prices. The latest news is that a country in Southeast Asia has launched its first cheap generic drug.
Mr. Wu couldn't help but chuckle, turned his head and looked into the distance, and sure enough he saw people from Luo's Pharmaceuticals.
Broad-spectrum anti-cancer drugs are far more universal than targeted drugs. Every product launched will attract the attention of everyone in the pharmaceutical industry. This time, Sanqing has developed the first broad-spectrum anti-cancer drug in China.
Obviously, this involves the huge domestic market, which immediately attracts a pack of wolves, watching with eager eyes.
Mr. Wu looked around again and saw more and more familiar faces, including colleagues, media, and doctors.
The more he looked, the more frightened he became. Suddenly, a majestic-looking middle-aged man came into view, and he vaguely recognized him as the Xie Bureau of Kunming Food and Drug Administration.
Do you actually attach so much importance to Sanqing? Even the higher-ups were alarmed.
I couldn't help but feel a sense of sadness in my heart. The last time Xinmei launched its anti-cancer injection conference, there weren't so many important guests.
Huh, Wei, I want to see if you are really awesome or just trying to impress others.
If there's even the slightest mistake, I'll see how you end up, haha.
Mr. Wu muttered to himself, found his nameplate, and sat down.
After a while, the scene fell silent.
Because, the much-anticipated launch of new anti-cancer drugs has finally begun.
